| Line | All comers | BRAF |
|---|
| Screening, prevention and diagnosis | 1 | · |
| Early / localised | · | 1 |
| Advanced, first line | · | 1 |
| Other settings | · | 1 |
Screening, prevention and diagnosis
| Subgroup | Setting | Approach | Products and trials | Guideline | Evidence |
|---|
| All comers | Diagnosis | Core biopsy with rapid BRAF testing, airway assessment, staging CT and PET; multidisciplinary planning within days. | | | 58 |
Early / localised
| Subgroup | Setting | Approach | Products and trials | Guideline | Evidence |
|---|
| BRAF | BRAF wild-type, resectable | Surgery followed by chemoradiation (paclitaxel- or doxorubicin-based). | | | 93 |
Advanced, first line
| Subgroup | Setting | Approach | Products and trials | Guideline | Evidence |
|---|
| BRAF | Unresectable BRAF wild-type | Chemoradiation or immunotherapy in trials; lenvatinib in some countries; palliative radiotherapy and airway support. | | | 91 |
Other settings
| Subgroup | Setting | Approach | Products and trials | Guideline | Evidence |
|---|
| BRAF | BRAF V600E-mutant | Dabrafenib plus trametinib, with pembrolizumab in many centres; neoadjuvant use to make tumours resectable, then surgery and radiotherapy. | | | 98 |
Lines and subgroups are parsed from the setting text of each standard-of-care row and can misclassify an unusual phrasing; the row’s own setting is always shown. Guideline chips reflect the NCCN category and ESMO-MCBS grade recorded on the cancer page, checked on its stated date. Not medical advice.